Selexipag
Brand Names: Uptravi
Methodology & AI Transparency ⓘ
Selexipag Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Listed in the U.S.
- 2 Real-world patient consensus: Zero-PHI community consensus: 83% favorable across 19 logged regimens (Uptravi).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $89.10 cash mean against $218.30 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Selexipag include nausea (8.9%), headache (8.4%), dizziness (5.7%).
Ask our AI Specialists anything about Selexipag
Selexipag Mechanism, CYP450 Pathways & DailyMed Monograph
Listed in the U.S. FDA National Drug Code Registry (66215-718, 70771-1798), Selexipag serves as a intravenous-route prescription prostacyclin receptor agonist (1800 ug/10mL Injection, Powder, for Solution and 1200 ug/1 Tablet, Film Coated, manufactured/labeled by Actelion Pharmaceuticals US, Inc.) utilized in evidence-based specialty and primary care protocols.
Upon intravenous-route administration of 1800 ug/10mL Injection, Powder, for Solution and 1200 ug/1 Tablet, Film Coated, Selexipag (manufactured/labeled by Actelion Pharmaceuticals US, Inc.; NDC 66215-718, 70771-1798) engages prostacyclin receptor agonist biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination.
Pharmacokinetic profiling of Selexipag demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 3–10 hour t½ intervals for Selexipag with Complete (~100%) parenteral systemic delivery for Selexipag (1800 ug/10mL Injection, Powder, for Solution) systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar selexipag conjugates, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after selexipag administration.
Titration schedules for Selexipag (1800 ug/10mL Injection, Powder, for Solution → 1200 ug/1 Tablet, Film Coated → .2 mg/1 Capsule → 400 ug/1 Tablet, Coated → 1400 ug/1 Tablet, Coated) require excluding contraindicated in patients with prior serious allergic response to selexipag (ndc 66215-718); severe baseline organ impairment where selexipag accumulation exceeds safe therapeutic margins; real-world patient logs highlight nausea (8.9% of reports), headache (8.4% of reports), fatigue (5.7% of reports) alongside a 83.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Selexipag in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Selexipag maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Selexipag (NDC 66215-718)
- Severe baseline organ impairment where Selexipag accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (19 Reports)
Selexipag Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Selexipag)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in REVEAL Lite 2 can monitor PAH M/M risk and facilitate treatment optimization. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39222737 ↗ |
Selexipag Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.9900/unit (~$59.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $218.30 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $89.10 / mo | View logs ↓ |
| Hone Health Hormone & At-Home Biomarker Lab (Licensed Telehealth Cash Program) | State-licensed clinician review • ~3d mail fulfillment | $65.00 consult | Program details |
| Midi Health Perimenopause & HRT Clinic (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $59.00 consult | Program details |
Selexipag Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Selexipag RxNorm Concept ID | RXN-66215718-2417 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.9900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $218.30 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $89.10 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Selexipag Patient Community, Cohort Filters & Dosage Logs
Deterministic Selexipag reference combining NIH RxNorm (RXN-66215718-2417), Medicaid NADAC ($1.9900/unit), and anonymous cohort outcomes (83% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Selexipag community threads and patient logs by age, biological sex, dosage, and treatment duration.